CymaBay Therapeutics (NASDAQ:CBAY) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.30) by 6.67 percent. This is a 15.15 percent increase over losses of $(0.33) per share from the same period last year.
Visa To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
